Lack of FLT3-TKD835 gene mutation in toxicity of sulfur mustard in Iranian veterans

Document Type : Original Article


1 Cancer Molecular Pathology Research Center, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Medical Toxicology Research Center, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran


Objective(s):Sulfur mustard (SM) was used by the Iraqi army against the Iranian troops in the Iran-Iraq war from 1983–1988. This chemical gas affects different organs including the skin, lungs and the hematopoietic system. Any exposure to SM increases the risk of chromosomal breaking, hyperdiploidy and hypodiploidy. Studies have shown that the risk for acute myeloblastic and lymphoblastic leukemia increases in veterans exposed to SM. FLT3 mutations including ITD and TKD mutations had been observed in some cases of leukemia. Therefore, we aimed to investigate the frequency of FLT3-TKD835 mutations in the veterans exposed to SM agent.
Materials and Methods: We studied 42 patients who were exposed to SM during the war in Khorasan Razavi province, Mashhad, Iran in 2012. As control group, 30 healthy males were selected from first-degree relatives of the patients. For assessment of TKD835 mutation, DNA was extracted and RFLP-PCR was performed.
Results: Analysis of RFLP-PCR data showed no FLT-3 TKD mutation in any of the patients.
Conclusion: Although contact with SM can increase the risk of malignancy especially hematologic neoplasms, results of the study show that another mechanism of leukemogenesis, other than FLT3-TKD mutation, may be the reason for increased risk of leukemia in SM toxicity.


1. Ghanei M, Harandi AA. Long term consequences from exposure to sulfur mustard: a review. Inhal Toxicol 2007; 19:451-456.
2. Hassan ZM, Ebtekar M, Ghanei M, Taghikhani M, Noori Daloii M, Ghazanfari T. Immunobiological consequences of sulfur mustard contamination. Iran J Allergy Asthma Immunol 2006; 5:101-108.
3. Sanjarmoosavi N, Sanjarmoosavi N, Shahsavan M, Hassanzadeh-Nazarabadi M. Teratogenic effects of sulfur mustard on mice fetuses. Iran J Basic Med Sci 2012; 15:853-859.
4. Balali‐Mood M, Hefazi M. The pharmacology, toxicology, and medical treatment of sulphur mustard poisoning. Fundam Clin Pharmacol 2005; 19:297-315.
5. Robinson JP. Public health response to biological and chemical weapons: WHO guidance: World Health Organization; 2004.
6. Mahmoudi M, Hefazi M, Rastin M, Balali-Mood M. Long-term hematological and immunological complications of sulfur mustard poisoning in Iranian veterans. Int Immunopharmacol 2005; 5:1479-1485.
7. Balali-Mood M. Clinical and paraclinical findings in 233 patients with sulfur mustard poisoning. 1986.
8. Balali‐Mood M, Hefazi M. Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol Toxicol 2006; 99:273-282.
9. Balali-Mood M, Balali-Mood B. Sulphur mustard poisoning and its complications in Iranian veterans. Iran J Med Sci 2009; 34:155-171.
10. Balali-Mood M, Mousavi S, Balali-Mood B. Chronic health effects of sulphur mustard exposure with special reference to Iranian veterans. Emerg Health Threats J 2008;1.
11. Hefazi M. The clinical toxicology of sulfur mustard. Arch Iran Med 2005; 8:162-179.
12. Sidell FR, Takafuji ET, Franz DR. Medical aspects of chemical and biological warfare. office of the surgeon general (army) falls church va; 1997.
13. Keramati MR, Balali-Mood M, Mousavi SR, Sadeghi M, Riahi-Zanjani B. Biochemical and hematological findings of Khorasan veterans 23 years after sulfur mustard exposure. J Res Med Sci 2013; 18:855-859.
14. Small D. FLT3 mutations: biology and treatment. ASH Educ Program Book 2006; 2006:178-184.
15. Liang D, Shih L, Hung I, Yang C, Chen S, Jaing T, et al. FLT3-TKD mutation in childhood acute myeloid leukemia. Leukemia 2003; 17:883-886.
16. Moreno I, Martín G, Bolufer P, Barragán E, Rueda E, Román J, et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica 2003; 88:19-24.
17. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Presented in part at the 42nd Annual Meeting of the American Society of Hematology, December 1-5, 2000, San Francisco, CA (abstract 2334). Blood 2002; 99:4326-4335.
18. Heldin C-H. Dimerization of cell surface receptors in signal transduction. Cell 1995; 80:213-223.
19. Turner AM, Lin NL, Issarachai S, Lyman SD, Broudy V. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 1996; 88:3383-90.
20. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997; 11:1605-1609.
21. Shih L-Y, Huang C-F, Wu J-H, Wang P-N, Lin T-L, Dunn P, et al. Heterogeneous patterns of FLT3 Asp835 mutations in relapsed de Novo acute myeloid leukemia A comparative analysis of 120 paired diagnostic and relapse bone marrow samples. Clin Cancer Res 2004; 10:1326-1332.
22. Wang L, Lin D, Zhang X, Chen S, Wang M, Wang J. Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients. Leuk Res 2005; 29:1393-1398.
23. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97:2434-2439.
24. Abu‐Duhier F, Goodeve A, Wilson G, Care R, Peake I, Reilly J. Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001; 113:983-988.
25. Kooshyar MM, Ayatollahi H, Keramati MR, Sadeghian MH, Miri M, Sheikhi M. Lack of KRAS gene mutations in chronic myeloid leukemia in Iran. Asian Pac J Cancer prev 2013; 14:6653-6656.
26. Sheikhha MH, Awan A, Tobal K, Liu Yin JA. Prognostic significance of FLT3 ITD and D835 mutations in AML patients. Hematol J 2003; 4:41-46.
27. Sheikhi M, Zaker F, Javadi GR, Hashemi M, Razmkhah F. Assesment of FLT3-gene mutations among children with acute leukemia. Med Sci J Islam Azad Univ Tehran Med Branch 2009; 19:230-235.
28. Rees J. Aneuploidy in Acute Myeloid Leukemia.  Tumor aneuploidy: Springer; 1985. p. 25-28.
29. Balali-Mood M, Hefazi M. Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol Toxicol 2006; 99:273-282.
30. Stricker TP, Kumar V. Neoplasia. In: Kumar V, Abbas AK, Fausto N, Aster JC, editors. Robbins and Cotran Pathologic Basis of Disease. 8th ed. Philadelphia: Saunders Elsevier; 2010. p. 259-320.
31. Riahi-Zanjani B, Balali-Mood M, Mousavi SR, Karimi G, Sadeghi M, Shirmast E, et al. Serum cytokine profiles of Khorasan veterans 23 years after sulfur mustard exposure. Cytokine 2014; 70:161-164.
32. Sabourin CL, Petrali JP, Casillas RP. Alterations in inflammatory cytokine gene expression in sulfur mustard–exposed mouse skin. J Bochem Mol Toxicol 2000; 14:291-302.
33. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, et al. Interleukin 6 upregulates myeloid cell leukemia‐1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005; 42:1329-1338.
34. Budel LM, Touw IP, Delwel R, Clark SC, Lowenberg B. Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship to the proliferative response. Blood 1989; 74:565-571.
35. Rogers JV, Choi YW, Kiser RC, Babin MC, Casillas RP, Schlager JJ, et al. Microarray analysis of gene expression in murine skin exposed to sulfur mustard. J Biochem Mol Toxicol 2005; 18:289-299.
36. Wu H, Li P, Shao N, Ma J, Ji M, Sun X, et al. Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia. Oncol Lett. 2012; 3:1119-1123.